Clinical Trial Success Assurance
De-risking clinical trials with data, AI, and deep operational insight, saving costs and bringing innovative medicines to patients faster
Uncertainties and risks can derail clinical trial timelines, delaying market entries and delaying patients’ access to innovative medicines. With data from over one million clinical trials, advanced analytics and AI, Rewire’s Trial Success Assurance empowers clinical researchers to significantly reduce trial risks - from early planning through to execution stages.
A novel approach to clinical trial optimization grounded in big data and AI
Increasing medical complexity and requirements imposed by regulators are giving rise to unprecedented operational complexity. To serve the healthcare industry’s need for effective clinical trial design, Rewire entered a partnership with GoTrial, a platform that collects, harmonizes and curates clinical trial data from worldwide registries, building up a knowledge base of over 1 million clinical trials. Rewire’s Trial Success Assurance (TSA) presents a novel lever to optimize study design and execution with an objective assessment firmly grounded in big data.
TSA comes with a built-in option for risk-mitigation through our partner Munich Re
A growing number of clinical trial sponsors seek not only to reduce risk but also to transfer residual risk. In partnership with Munich Re, a global reinsurance and specialty insurance group, TSA provides options to insure against the risks of enrolment shortfalls. By combining unprecedented data, deep subject matter expertise and high-quality data science capabilities and AI with reliable insurance services our TSA product elevates clinical research and ensures trial timelines are met.
Rewire your clinical trials with AI
TSA complements best practices with objective perspectives grounded in big data & advanced analytics
Our track record speaks volumes
40%
Increased patient pool
We identified overly complex and restrictive eligibility criteria that excluded patients who were likely to benefit from treatment in a study that struggled to find eligible patients.
25%
Enrolment target added
We suggested an optimized set of high-potential sites predicted to enrol a significant part of a study's target patients.
Unlock the power of data & AI for your clinical studies today.
Get in touch.
Looking for an objective assessment of your clinical trial, powered by big data & AI?